SNGX - SOLIGENIX, INC.

1.39
0.020   1.439%

Share volume: 61,193
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$1.37
0.02
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 14%
Liquidity 45%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.72%
1 Month
17.09%
3 Months
6.20%
6 Months
-13.29%
1 Year
-36.43%
2 Year
-77.65%
Key data
Stock price
$1.39
P/E Ratio 
0.00
DAY RANGE
$1.34 - $1.39
EPS 
-$4.26
52 WEEK RANGE
$1.00 - $6.23
52 WEEK CHANGE
-$36.87
MARKET CAP 
4.971 M
YIELD 
N/A
SHARES OUTSTANDING 
10.086 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
1.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$320,471
AVERAGE 30 VOLUME 
$411,416
Company detail
CEO: Christopher J. Schaber
Region: US
Website: www.soligenix.com
Employees: 20
IPO year: 2009
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Soligenix, Inc. focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions.

Recent news